Eliem Therapeutics Inc

NASDAQ ELYM

Download Data

Eliem Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR for the year ending December 31, 2023: 8.00%

Eliem Therapeutics Inc Current Assets to Total Assets Ratio 2 year CAGR is 8.00% for the year ending December 31, 2023, a 43.27% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Eliem Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2022 was 1.00, a 16.34% change year over year.
  • Eliem Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.86, a -4.18% change year over year.
  • Eliem Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.89, a -10.22% change year over year.
  • Eliem Therapeutics Inc Current Assets to Total Assets Ratio for the year ending December 31, 2019 was 0.99.
NASDAQ: ELYM

Eliem Therapeutics Inc

CEO Mr. Robert W. Azelby M.B.A.
IPO Date Aug. 10, 2021
Location United States
Headquarters 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees 9
Sector Healthcare
Industry Biotechnology
Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

CYT

Cyteir Therapeutics Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email